||Revisiting Priorities in the Prevention of Mother-to-Child HIV Transmission|
In a talk focusing largely on the developing world, Louise Kuhn, M.P.H., drives home the importance of antiretroviral therapy for all pregnant or breastfeeding women with a CD4+ cell count below 350. She also urges a greater focus on long-term child health and survival, beyond simply preventing mother-to-child HIV transmission. (From The Body PRO)
IAS 2009 itself has officially ended, but our coverage has just begun!
More Top Stories:
- Upgrading Circumcision Tools to Prevent HIV
An interview with Leslie Shelton. (From The Body PRO)
- Got Lube?
The slippery slope for African men who don't. (From Test Positive Aware Network)
- A Review of Six Years of Statewide Testing for Acute HIV in North Carolina
An interview with JoAnn Kuruc, M.S.N., R.N. (From The Body PRO)
- HIV Treatment as Prevention: How Many Lives Could Be Saved?
If every person in sub-Saharan Africa received voluntary, annual HIV testing and started antiretroviral therapy immediately after diagnosis, HIV incidence would drop 95% in 10 years and more than seven million deaths would be averted, according to a theoretical model presented by Reuben Granich, M.D., M.P.H. (From The Body PRO)
- "Test and Treat" Unlikely to Halt Washington, D.C., HIV Epidemic, Study Suggests
A mathematical model from the Harvard School of Public Health, based on the population of Washington, D.C., has found that recalling every adult for annual HIV screening and treating every HIV-positive person with antiretrovirals as soon as they were diagnosed would only result in a 30% decline in the proportion of the HIV-positive population who had non-suppressed viral loads. (From aidsmap.com)
- Biomedical HIV Prevention, Including Microbicides, Vaccines, Circumcision and PrEP
The lesson we have to learn from the trials that have been completed is that we need to do much more fundamental research, on immunologic mechanisms to further development of vaccines and potentially of microbicides. (From The Body PRO)
- Longer, Stronger HIV Drug Regimen for Breastfeeding Women Cuts Mother-to-Child Transmission Rate, Study Finds
"Key findings from the study showed that a stronger drug cocktail administered over a longer period reduced the risk of mother-to-child HIV transmission compared with the current WHO-recommended short-course ARV regimen," Reuters reports. (From kaisernetwork.org)
- Range of Studies Examine Developments in HIV Prevention and Addressing Issues in Developing World
A brief summary of findings presented at IAS 2009 regarding microbicides, mother-to-child HIV transmission, HIV vaccine funding and efforts to fight HIV in developing countries. (From kaisernetwork.org)
- Studies Explore Future of HIV Treatment in Developing Countries
Whether used as a pivotal means to prevent further spread of HIV or as a means by which to improve the lives of HIV-infected patients, many studies presented at IAS 2009 examined issues of early treatment and expanded antiretroviral access. A few are summarized in this article. (From kaisernetwork.org)
- "Treatment as Prevention" Must Not Violate Human Rights, Conference Told
The expansion of HIV testing programs and the advocacy of universal testing and treatment of those who test positive as a means of prevention must not violate the human rights of target populations, said representatives from Human Rights Watch and the AIDS and Rights Alliance of Southern Africa. (From aidsmap.com)
- AIDS Vaccine Funding Down 10% in 2008
Funding for AIDS vaccine research fell by 10% in 2008, the first decline in a decade, according to figures released by the HIV Vaccine and Microbicide Resource Tracking Working Group. (From aidsmap.com)
- Acyclovir Reduces Disease Progression and Death in People With HIV by Nearly 20% -- But Doesn't Reduce Transmission Risk
HIV-infected people given 400 mg of acyclovir twice-daily as part of a trial to see if the drug reduced HIV transmission in serodiscordant couples were 17% less likely to progress to AIDS, have to start antiretroviral therapy, or die. (From aidsmap.com)
- Early Tests of Maraviroc as Microbicide Produce Less Activity Than Expected
Preclinical ex-vivo tests of the entry inhibitor drug maraviroc as a possible microbicide have found that the drug only produced a moderate protective effect against HIV: a 50% to 60% inhibition of HIV infection of penile tissue and an 85% inhibition in colorectal tissue, when given at high doses. (From aidsmap.com)
- Vaginal Washing Increases HIV Infection Risk; Results for Dry Sex Less Clear-Cut
A meta-analysis of data on vaginal practices and HIV infection from ten African cohorts has found that both vaginal washing with soap and wiping the vagina with cloths, tissues or paper were associated with an increased risk of acquiring HIV. (From aidsmap.com)
- Increased Risk of HIV Transmission in Serodiscordant Couples Wishing to Conceive
Harm reduction interventions to avoid HIV transmission in heterosexual, serodiscordant couples who wish to have children are urgently needed, particularly in resource-poor settings, according to Sara Brubaker, M.D., M.P.H., of the University of California-San Francisco. (From aidsmap.com)
- Low Bone Mineral Density in Botswana PrEP Trial Participants Raises Concerns
Researchers conducting a trial of tenofovir and emtricitabine as pre-exposure prophylaxis (PrEP) in Botswana have found low bone mineral density levels in HIV-uninfected volunteers at enrollment. (From aidsmap.com)
- At Conclusion of Major International Scientific Meeting on AIDS, Researchers Highlight Evidence of Important Benefits from HIV Investments for Other Health Conditions, Including Those Affecting Women and Children
Scientists urge support for additional investments to strengthen health systems, using recent AIDS investments as a model. (From International AIDS Society)
- More Coming Soon!
Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.